-
Mashup Score: 0
Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive advanced melanoma. Results of the final analysis are awaited to establish whether a significant improvement in overall survival can be achieved with…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Vemurafenib Retreatment Deemed Effective in R/R Hairy Cell Leukemia | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination October 27, 2022 Retreatment with the oral BRAF inhibitor vemurafenib was associated with high rates of response in patients with relapsed or refractory (R/R) hairy cell leukemia (HCL), according to study…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
In patients with relapsed or refractory #HairyCellLeukemia, retreatment with the oral BRAF inhibitor #vemurafenib led to high rates of response and was not associated with any unusual toxicities https://t.co/GAosmbKXOG
-
-
Mashup Score: 0
Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in the September issue: #Atezolizumab, #vemurafenib, and #cobimetinib in patients with #melanoma with #CNS #metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study https://t.co/NgS9ywLTsT
-
-
Mashup Score: 0
Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Atezolizumab, #vemurafenib, and #cobimetinib in patients with #melanoma with #CNS #metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study https://t.co/NgS9ywLTsT https://t.co/KxW0CKGZq7
-
-
Mashup Score: 0
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) study. On the basis of observed early clinical activity, we expanded the cohort of patients with NSCLC. We present results from this cohort. METHODS This open-label,…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of #Vemurafenib in Patients With Non–Small-Cell #lungcancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study #precisionmedicine @ASCO_pubs @ASCO #LCSM #BRAF https://t.co/A0EdmhDSzv
-
-
Mashup Score: 1Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study - 4 year(s) ago
PURPOSE Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation–positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Vemurafenib for #Refractory Multisystem Langerhans Cell Histiocytosis #LCH in Children: An International Observational Study 38/54 achieved CR The response to VMF persisted as long as the patient remained on treatment 24/30 relapsed after stopping https://t.co/gNskE5HDrW
-
-
Mashup Score: 0JNCCN 360 - 4 year(s) ago
By: Lauren Harrison, MS Posted: Tuesday, May 26, 2020 In cancers with BRAF V600 mutations, single-agent treatment BRAF inhibition with vemurafenib may prove to have broader clinical activity than was previously recognized, with responses reported in 13 different types of cancer. Vivek Subbiah, MD, of The…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Vemurafenib is effective in 13 cancer types, including #thyroidcancer: https://t.co/B9BNkKNXNg #thycsm #JNCCN360 https://t.co/OWr6FZ21Hh
-
Online first: Overall #survival with first-line #atezolizumab in combination with #vemurafenib+#cobimetinib in BRAFV600 mutation-positive advanced #melanoma: second interim analysis of IMspire150 https://t.co/8D8ccSYz8B